Information Provided By: 
Fly News Breaks for June 28, 2016
CELG
Jun 28, 2016 | 07:13 EDT
Jefferies analyst Brian Abrahams says his analysis suggests that Celgene's Phase III Revlimid lymphoma study is more likely to work than not. The analyst sees a "relatively modest" stock move regardless of the trial outcome, however. Abrahams continues to recommend taking advantage of Celgene's recent stock volatility. He keeps a Buy rating on the shares with a $140 price target.
News For CELG From the Last 2 Days
There are no results for your query CELG
